- Home
- BNGO vs ATHA Comparison
BNGO vs ATHA Comparison
Compare BNGO & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNGO
- ATHA
- Stock Information
- Founded
- BNGO 2003
- ATHA 2011
- Country
- BNGO United States
- ATHA United States
- Employees
- BNGO N/A
- ATHA N/A
- Industry
- BNGO Biotechnology: Laboratory Analytical Instruments
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- BNGO Industrials
- ATHA Health Care
- Exchange
- BNGO Nasdaq
- ATHA Nasdaq
- Market Cap
- BNGO 24.3M
- ATHA 21.0M
- IPO Year
- BNGO 2018
- ATHA 2020
- Fundamental
- Price
- BNGO $4.30
- ATHA $0.28
- Analyst Decision
- BNGO Buy
- ATHA Buy
- Analyst Count
- BNGO 4
- ATHA 4
- Target Price
- BNGO $7.00
- ATHA $11.25
- AVG Volume (30 Days)
- BNGO 215.7K
- ATHA 223.8K
- Earning Date
- BNGO 05-07-2025
- ATHA 05-14-2025
- Dividend Yield
- BNGO N/A
- ATHA N/A
- EPS Growth
- BNGO N/A
- ATHA N/A
- EPS
- BNGO N/A
- ATHA N/A
- Revenue
- BNGO $30,776,000.00
- ATHA N/A
- Revenue This Year
- BNGO $0.53
- ATHA N/A
- Revenue Next Year
- BNGO $8.46
- ATHA N/A
- P/E Ratio
- BNGO N/A
- ATHA N/A
- Revenue Growth
- BNGO N/A
- ATHA N/A
- 52 Week Low
- BNGO $2.68
- ATHA $0.22
- 52 Week High
- BNGO $72.60
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- BNGO 55.98
- ATHA 49.62
- Support Level
- BNGO $3.80
- ATHA $0.22
- Resistance Level
- BNGO $5.22
- ATHA $0.31
- Average True Range (ATR)
- BNGO 0.45
- ATHA 0.03
- MACD
- BNGO 0.11
- ATHA 0.01
- Stochastic Oscillator
- BNGO 63.78
- ATHA 70.66
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.